
This study investigated oritavancin, a semi-synthetic lipoglycopeptide antibiotic, focusing on its molecular targets and pharmacokinetics for effective clinical application. Utilizing computational methods, seven molecular targets in humans were identified, with the highest binding affinity observed for PI3-kinase p110-gamma subunit (−10.34 kcal/mol). Pharmacokinetic modeling indicated that infusion administration resulted in lower peak concentrations compared to bolus dosing, with Cmax values varying by dose. The findings enhance understanding of oritavancin's pharmacological profile, supporting its optimization for treating serious Gram-positive infections.
Like
Save
Share